Maxidex (Dexamethasone)

Dexamethasone penetrates ocular tissues and binds to glucocorticoid receptors inside cells. The receptor complex alters gene expression, inhibiting phospholipase A2 and reducing the production of prostaglandins, leukotrienes and inflammatory cytokines, which together suppress ocular inflammation.

The specific dosing regimen for Maxidex is determined by the prescribing clinician based on the severity of the condition, patient age and response to therapy. Typical regimens involve one to two drops in the affected eye(s) at prescribed intervals.

Safety of Maxidex in pregnancy and lactation has not been established. The product is classified as pregnancy category unknown, so clinicians must weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To request Maxidex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both dexamethasone (Maxidex) and prednisolone are potent corticosteroids for eye inflammation, but dexamethasone generally has a higher receptor affinity and may achieve similar anti‑inflammatory effects at a lower concentration. Choice of agent depends on physician preference, formulation availability and individual patient response.

Store Maxidex at room temperature, below 25 °C. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not refrigerate unless specifically instructed by the supplier.

Maxidex is applied as an ophthalmic suspension. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. The eye should be closed gently for a few seconds to allow absorption, and contact lenses should be removed before dosing.

Serious risks include the development of cataracts, secondary glaucoma leading to optic nerve damage, and severe hypersensitivity reactions such as eyelid edema or conjunctival swelling. Patients should be monitored regularly for intra‑ocular pressure changes and any signs of infection or allergic response.

Maxidex should be avoided in patients with known hypersensitivity to dexamethasone or any component of the formulation, in eyes with active viral infections (e.g., herpes simplex keratitis), and in individuals where intra‑ocular pressure cannot be monitored adequately. Caution is also advised in patients with uncontrolled glaucoma.